FGFR-Altered Urothelial Carcinoma

1. Disease Information

1.1 Definition and overview

FGFR‑altered urothelial carcinoma is not a separate histopathologic diagnosis, but a molecularly defined subset of urothelial carcinoma characterized by oncogenic alterations in FGFR2 and/or FGFR3 that can predict sensitivity to FGFR‑targeted therapy (notably erdafitinib). In a real‑world genomic/clinical cohort, Guercio et al. describe FGFR‑altered UC as tumors harboring oncogenic FGFR3 mutations or FGFR2/3 fusions, which are “established predictive biomarkers for erdafitinib.” (guercio2023clinicalandgenomic pages 2-4)

1.2 Key identifiers (availability in retrieved evidence)

• ICD codes / MeSH / OMIM / Orphanet / MONDO: A distinct “FGFR‑altered UC” code was not identified in the retrieved evidence. In practice, coding is typically done at the disease-site level (e.g., bladder cancer / urothelial carcinoma) with FGFR status stored as a biomarker attribute.

1.3 Synonyms and alternative names

Common usage in the literature includes: * FGFR2/3‑altered urothelial carcinoma (testi2024targetedtherapiesand pages 11-13, benjamin2023treatmentapproachesfor pages 3-4) * FGFR3‑altered bladder cancer (guercio2023clinicalandgenomic pages 6-7) * FGFR3‑mutant urothelial carcinoma (bannier2024aiallowsprescreening pages 1-2)

1.4 Data provenance (patient-level vs aggregated)

Evidence includes: * Aggregated disease-level and biomarker-level resources (e.g., cohort multi‑omics in metastatic UC; reviews) (antar2024theevolvingmolecular pages 3-5, shang2024landscapeoftargeted pages 3-5) * Patient-level institutional clinical genomics + outcomes (real‑world erdafitinib outcomes, paired primary/metastasis discordance, cfDNA evolution) (guercio2023clinicalandgenomic pages 1-2, guercio2023clinicalandgenomic pages 6-7)

2. Etiology

2.1 Disease causal factors (mechanistic)

FGFR‑altered UC is driven by somatic activating alterations in FGFR signaling (primarily FGFR3), promoting urothelial tumor initiation/maintenance via pro‑proliferative and pro‑survival signaling (MAPK/PI3K/STAT) (shang2024landscapeoftargeted pages 3-5, shan2024moleculartargetingof pages 4-5).

2.2 Risk factors for urothelial carcinoma (UC)

Major risk factors for UC in general (not specific to FGFR subtype) include: * Tobacco smoking (listed as a major UC risk factor) (mitiushkina2024useof3′ pages 1-2, ferreira2023epimarkersforbladder pages 19-26) * Occupational exposure to aromatic amines (mitiushkina2024useof3′ pages 1-2) * Contaminated drinking water (mitiushkina2024useof3′ pages 1-2) * Family history + lifestyle interactions: in a population cohort, individuals with an affected first‑degree relative had elevated risk, and smokers with positive family history showed a strong interaction (HR 3.60; RERI 0.72), indicating gene–environment interplay at the level of familial susceptibility and smoking exposure (guercio2023clinicalandgenomic pages 1-2).

2.3 Protective factors

High-quality protective-factor evidence specific to FGFR‑altered UC was not identified in the retrieved evidence. For UC overall, prevention strategies generally focus on risk-factor avoidance (e.g., smoking cessation, reducing occupational carcinogen exposure), but quantitative protective estimates were not captured in the extracted evidence.

2.4 Gene–environment interactions

Direct GxE interactions tied specifically to FGFR alterations were not captured in the extracted 2023–2024 evidence. However, familial predisposition interacting with smoking for bladder cancer risk has been quantified (guercio2023clinicalandgenomic pages 1-2).

3. Phenotypes (clinical presentation)

3.1 Core clinical phenotypes of UC

Key presenting features of urothelial bladder cancer include: * Hematuria (gross or microscopic) as the most common presenting sign; one source notes “the most common presenting sign is hematuria (gross or microscopic)” (ferreira2023epimarkersforbladder pages 26-29). * Dysuria and polyuria also occur (ferreira2023epimarkersforbladder pages 26-29). * Stage association: visible hematuria is described as being “usually associated with more advanced stage/grade.” (ferreira2023epimarkersforbladder pages 26-29)

Upper tract UC (UTUC) is not extensively phenotyped in the extracted symptom-focused evidence, but UTUC is described as more aggressive with high invasiveness at diagnosis (60% invasive at diagnosis) (mitiushkina2024useof3′ pages 1-2).

3.2 Age of onset and distribution

• Bladder cancer is predominantly a disease of older adults; one summary reports ~80% of patients are older than 65 years (ferreira2023epimarkersforbladder pages 19-26).

3.3 Stage distribution at diagnosis (UC overall)

• NMIBC predominates: majority are NMIBC (70–80%), while MIBC accounts for ~20–30% at diagnosis (ferreira2023epimarkersforbladder pages 26-29).
• Metastatic at diagnosis: about 5% of bladder cancers are metastatic at diagnosis (mitiushkina2024useof3′ pages 1-2).

3.4 Suggested HPO terms (examples)

• Hematuria — HP:0000790
• Dysuria — HP:0100518
• Polyuria — HP:0000103
• Urinary urgency — HP:0000012 (common in bladder cancer symptom clusters; not directly quantified in extracted evidence)

3.5 Quality-of-life impact

Direct validated QoL instrument data (e.g., EQ‑5D/SF‑36) specific to FGFR‑altered UC were not identified in extracted evidence; however, urinary symptoms (hematuria, dysuria, polyuria) are clinically burdensome (ferreira2023epimarkersforbladder pages 26-29).

4. Genetic / Molecular Information (FGFR alterations)

4.1 Causal/driver genes

• FGFR3 is the dominant driver in this subtype; FGFR2 alterations occur but are comparatively rare in UC (guercio2023clinicalandgenomic pages 1-2, guercio2023clinicalandgenomic pages 2-4).

4.2 Alteration types and prevalence (key statistics)

Guercio et al. reported stage-stratified frequencies of FGFR3 alterations predictive of erdafitinib sensitivity: * NMIBC: 39% (199/504) * MIBC: 14% (75/526) * Localized UTUC: 43% (81/187) * Metastatic specimens: 26% (59/228) (guercio2023clinicalandgenomic pages 1-2)

A complementary Japanese multi‑omics cohort similarly reported FGFR3 alterations (mutations + fusions) of 44% in NMIBC and 15% in MIBC (komura2023theimpactof pages 1-2).

Metastatic biopsy profiling showed FGFR3 actionable targets in 26% of metastatic biopsies and noted that “potential therapeutic targets” were found in 73% overall (antar2024theevolvingmolecular pages 3-5).

A targeted RNA‑sequencing study found FGFR2/3 activating point mutations or fusions in 23.2% (54/233) of urothelial carcinomas, with enrichment in upper tract vs bladder (48% vs 20%) (mitiushkina2024useof3′ pages 2-3).

4.3 Pathogenic variants (examples; primarily somatic)

In a real-world metastatic erdafitinib-treated cohort, common FGFR3 alterations included: * S249C (59%), Y373C (9%), R248C (9%) * FGFR3–TACC3 fusions (13%) (guercio2023clinicalandgenomic pages 6-7)

4.4 Somatic vs germline

The evidence base here pertains to tumor somatic alterations and tumor-derived cfDNA evolution under therapy (guercio2023clinicalandgenomic pages 2-4). Germline FGFR2/3 causes of UC were not supported by extracted evidence.

4.5 Tumor heterogeneity and discordance

Clinically important sampling issue: among paired primary tumors and metachronous metastases, 26% showed discordant FGFR3 status, raising concern about using archival primary tissue alone for selection (guercio2023clinicalandgenomic pages 1-2, guercio2023clinicalandgenomic pages 2-4).

5. Mechanism / Pathophysiology

5.1 Molecular pathways downstream of FGFR3 alterations

FGFR3 activation can occur via missense mutations or FGFR3–TACC3 fusions: * Fusions: FGFR3–TACC3 fusions drive constitutive activation of MAPK, PI3K/AKT, and STAT3 signaling; altered TACC3 function may contribute to mitotic defects/aneuploidy (shang2024landscapeoftargeted pages 3-5). * Missense mutations: gain‑of‑function missense mutations can drive ligand-independent dimerization and increased kinase activity (shan2024moleculartargetingof pages 4-5).

5.2 Molecular subtype context and tumor microenvironment (TME)

FGFR3 alterations are strongly associated with luminal biology: * In a large Japanese cohort, FGFR3 alterations were linked to luminal papillary enrichment: “LumP was significantly more prevalent in aFGFR3” (komura2023theimpactof pages 1-2). * FGFR3-altered tumors are often characterized as having reduced T‑cell infiltration and a “non–T cell–inflamed” microenvironment in multiple mechanistic discussions (okato2024fgfrinhibitionaugments pages 1-2, komura2023theimpactof pages 1-2).

5.3 Immune checkpoint inhibitor (ICI) response heterogeneity and proposed immune targets

Komura et al. reported clinically relevant response heterogeneity: * In CPI-treated patients, overall ORR was similar between intact vs altered FGFR3: 20% vs 31% (p=0.467) (komura2023theimpactof pages 1-2). * In the LumP subtype, ORR differed markedly: LumP/aFGFR3 50% vs LumP/iFGFR3 5% (p=0.022) (komura2023theimpactof pages 1-2). * Transcriptome analysis highlighted TIM3 as the most upregulated immune-related gene in iFGFR3, and authors propose TIM3 as a target for iFGFR3 and IDO1/CCL24 for LumP/iFGFR3 (komura2023theimpactof pages 1-2).

5.4 Resistance mechanisms to FGFR inhibition

Evidence-supported resistance mechanisms include: * On-target second-site FGFR3 mutations (e.g., kinase-domain mutations, including gatekeeper-like changes) emerging in cfDNA during erdafitinib therapy (guercio2023clinicalandgenomic pages 6-7). * Bypass/parallel pathway alterations: emergent cfDNA alterations included TP53, AKT1, and second-site FGFR3 mutations (guercio2023clinicalandgenomic pages 6-7, guercio2023clinicalandgenomic pages 2-4). * A proposed metabolic/hypoxia-linked resistance program: upregulation of P4HA2 via a HIF1α feedback loop reducing ROS and mediating acquired resistance to erdafitinib (shang2024landscapeoftargeted pages 3-5).

5.5 Suggested GO terms (examples)

• FGFR signaling pathway (e.g., GO:0008543 fibroblast growth factor receptor signaling pathway)
• MAPK cascade (GO:0000165)
• PI3K/AKT signaling (e.g., GO:0014065 phosphatidylinositol 3-kinase signaling)
• STAT3 signaling (e.g., GO:0046427 positive regulation of JAK-STAT cascade)
• Regulation of T cell proliferation (GO:0042129) (relevant to Treg expansion effects described) (okato2024fgfrinhibitionaugments pages 1-2)

5.6 Suggested Cell Ontology (CL) terms (examples)

• Urothelial cell (CL class; urothelium-derived carcinoma)
• Regulatory T cell (CL:0000815) (Treg expansion/abrogation under combined therapy in murine model) (okato2024fgfrinhibitionaugments pages 1-2)

6. Diagnostics

6.1 Standard UC diagnostics (brief)

Standard clinical diagnosis relies on cystoscopy, pathology, and staging. Molecular FGFR testing is added to identify candidates for FGFR-targeted therapy.

6.2 FGFR alteration testing approaches

Tissue-based NGS and cfDNA * In real‑world practice, tumor sequencing (e.g., targeted panel NGS) was used to identify oncogenic FGFR alterations, and cfDNA was used for longitudinal monitoring under erdafitinib (guercio2023clinicalandgenomic pages 2-4).

RNA-based approaches (fusion detection and breadth) * A targeted RNA-seq (3′ RACE) approach detected FGFR2/3 alterations in 23.2% overall and found that 8/11 FGFR3 rearrangements were undetectable by commonly used PCR kits, highlighting fusion-detection limitations of some PCR strategies (mitiushkina2024useof3′ pages 1-2, mitiushkina2024useof3′ pages 2-3).

Companion diagnostic / RT‑PCR * The QIAGEN therascreen FGFR RGQ RT‑PCR assay is referenced as the companion diagnostic used to select patients eligible for erdafitinib (bannier2024aiallowsprescreening pages 2-3, jain2024acomprehensiveoverview pages 8-10).

AI-based prescreening on H&E slides (2024 development) A Nature Communications study developed a deep-learning H&E prescreening tool to triage FGFR3 mutation testing: * Reported that the model achieved sensitivity >93% on advanced/metastatic cases while reducing molecular testing by ~40% on average (bannier2024aiallowsprescreening pages 1-2). * External performance included AUC values around 0.82–0.89 in independent cohorts (bannier2024aiallowsprescreening pages 1-2).

6.3 Practical implementation note

Because FGFR3 status can be discordant between primary and metastasis (26% discordance), testing the most recent/metastatic specimen when feasible is supported by real‑world evidence (guercio2023clinicalandgenomic pages 1-2, guercio2023clinicalandgenomic pages 2-4).

7. Outcome / Prognosis

7.1 General UC outcomes by stage

A bladder-cancer biomarker resource summarized SEER-like stage survival gradients: ~96% 5‑year survival for mucosa‑confined disease and ~7% for distant metastasis (ferreira2023epimarkersforbladder pages 26-29). These are not FGFR‑specific.

7.2 FGFR-altered vs unselected prognosis

The extracted evidence is mixed and context-dependent: * FGFR3 alterations are enriched in earlier-stage disease (NMIBC, papillary phenotypes), which often carries better prognosis, but metastatic FGFR‑altered UC remains lethal. * In metastatic biopsies, FGFR3 is one of the most common actionable targets (26%), emphasizing clinical relevance in advanced disease (antar2024theevolvingmolecular pages 3-5).

7.3 Prognostic factors during FGFR inhibitor therapy

Real‑world erdafitinib outcomes were relatively short in a heavily pretreated cohort (median PFS 2.8 months; OS 6.6 months) and TP53 co-alterations were implicated as unfavorable in response analyses (guercio2023clinicalandgenomic pages 6-7).

8. Treatment (current applications and real‑world implementation)

8.1 Approved targeted therapy: erdafitinib

Erdafitinib is the only widely cited FDA-approved targeted therapy for metastatic UC with select FGFR2/3 alterations in the evidence base (guercio2023clinicalandgenomic pages 2-4, benjamin2023treatmentapproachesfor pages 3-4).

Key pivotal and real‑world outcomes are summarized in the table below.

Table: This table summarizes the main FGFR-targeted therapy datasets currently available in the evidence snippets for FGFR-altered urothelial carcinoma. It highlights efficacy, biomarker-defined eligibility, and tolerability across pivotal trials and real-world use.

Real‑world implementation challenges * Dose reductions and interruptions were common in real-world practice (38% reductions; 50% interruptions) (guercio2023clinicalandgenomic pages 6-7).

8.2 Combination approaches (2023–2024 emphasis)

• Erdafitinib + anti–PD-1/PD-L1 approaches are under active study; the NORSE dataset suggests improved ORR and PFS with erdafitinib + cetrelimab compared with monotherapy (ORR 54.5% vs 44.2%; median PFS 10.97 vs 5.62 months) (benjamin2023treatmentapproachesfor pages 3-4).

8.3 Experimental FGFR inhibitors and trials (selected; with NCT IDs)

• TYRA‑300 (FGFR3‑selective)
• NCT06995677: Phase 2; FGFR3 mutation/fusion; low‑grade intermediate‑risk NMIBC; primary endpoint complete response at 3 months (NCT06995677 chunk 1).
• NCT05544552 is described in a 2024 review as Phase I–II TYRA‑300 in advanced UC with activating FGFR3 alterations (~310 patients; endpoints include MTD/RP2D/ORR) (testi2024targetedtherapiesand pages 4-6).
• Erdafitinib in recurrent non-invasive bladder cancer
• NCT04917809: oral erdafitinib in recurrent non‑invasive bladder cancer; exclusion criteria include prior FGFR inhibitors and ocular disorders; additional phase/endpoints were not present in the extracted trial text chunk (NCT04917809 chunk 2).
• Erdafitinib pivotal THOR program
• NCT03390504 is referenced as the THOR program comparing erdafitinib vs chemotherapy and/or pembrolizumab in advanced UC with FGFR alterations (guercio2023clinicalandgenomic pages 1-2, jain2024acomprehensiveoverview pages 8-10).

8.4 MAXO (treatment action) term suggestions

• FGFR inhibitor therapy (e.g., “treatment with fibroblast growth factor receptor inhibitor”)
• Immune checkpoint inhibitor therapy (for combination strategies)
• Circulating tumor DNA monitoring (during therapy) (guercio2023clinicalandgenomic pages 2-4)

9. Prevention / Epidemiology

9.1 Epidemiology and demographics

• Bladder cancer is common worldwide; one resource reports in 2020: 573,278 new cases and 212,536 deaths, and that bladder cancer is about three times more frequent in men and ~80% of patients are older than 65 years (ferreira2023epimarkersforbladder pages 19-26).
• Urothelial carcinoma accounts for ~90% of bladder tumors (ferreira2023epimarkersforbladder pages 26-29, ferreira2023epimarkersforbladder pages 19-26).
• UTUC represents ~5–10% of UCs and is more aggressive, with ~60% invasive at diagnosis (mitiushkina2024useof3′ pages 1-2).

9.2 Prevention relevance to FGFR-altered disease

Primary prevention is similar to UC overall because FGFR alterations are somatic tumor events arising in the context of UC carcinogenesis.

Primary prevention targets: * Smoking cessation (major risk factor) (mitiushkina2024useof3′ pages 1-2, ferreira2023epimarkersforbladder pages 19-26) * Minimizing occupational carcinogen exposure and contaminated water exposure (mitiushkina2024useof3′ pages 1-2)

10. Other Species / Natural Disease

No cross-species naturally occurring FGFR‑altered UC epidemiology was identified in the extracted evidence.

11. Model Organisms / Experimental Models

11.1 Genetically engineered mouse models (mechanistic and translational)

A 2024 JCI study used a genetically engineered murine model combining FGFR3S249C activation with Trp53R270H (UPFL) and reported that: * Tumors “recapitulate papillary histology and LumP/UROMOL class 1 transcriptional states” and that co-alteration yields high-grade NMIBC (okato2024fgfrinhibitionaugments pages 1-2). * The model showed ICI hyperprogression via Treg expansion, which was abrogated by FGFR inhibition; combined erdafitinib + ICI yielded strong efficacy in mice (okato2024fgfrinhibitionaugments pages 1-2).

11.2 Model limitations

Animal models may not capture the full molecular heterogeneity, prior treatment exposures, and sampling discordance seen in human metastatic disease (highlighted in real-world primary vs metastasis discordance) (guercio2023clinicalandgenomic pages 1-2).

12. Recent developments and expert analysis (2023–2024 emphasis)

12.1 Key 2023–2024 advances

1. Randomized phase III evidence for erdafitinib vs chemotherapy in FGFR‑altered metastatic UC (THOR) with improved OS, PFS, and ORR (benjamin2023treatmentapproachesfor pages 3-4).
2. Real‑world genomic/clinical datasets highlighting short durability, toxicity-driven dose modification, and frequent primary/metastasis discordance (guercio2023clinicalandgenomic pages 1-2, guercio2023clinicalandgenomic pages 6-7).
3. TME heterogeneity and subtype-specific immunotherapy responses (e.g., LumP/aFGFR3 showing ORR 50% vs LumP/iFGFR3 5%) and new proposed immune targets (TIM3, IDO1, CCL24) (komura2023theimpactof pages 1-2).
4. Deployment of AI prescreening on routine histology to reduce molecular testing burden while maintaining high sensitivity for FGFR3 mutation detection (bannier2024aiallowsprescreening pages 1-2).
5. RNA-based panels expanding detection of FGFR3 rearrangements missed by common PCR kits, supporting broader adoption of RNA sequencing for fusion detection (mitiushkina2024useof3′ pages 2-3).

12.2 Expert opinions and analysis (authoritative sources)

• Reviews stress that erdafitinib benefit can be transient, and overcoming acquired resistance is a major research priority (noeraparast2024fgfr3alterationsin pages 1-2).
• Mechanistic work supports a rationale for combining FGFR inhibition with immunotherapy by modulating immunosuppression (Treg expansion) in FGFR3-mutant contexts (okato2024fgfrinhibitionaugments pages 1-2).

Visual summary: FGFR alteration frequencies across disease settings

The following table consolidates key stage-specific FGFR alteration frequencies from multiple cohorts.

Table: This table summarizes reported FGFR alteration frequencies across urothelial carcinoma disease settings using only the cited evidence. It highlights stage dependence, upper-tract enrichment, and the clinically important discordance between primary and metastatic tumors.

Key limitations of this evidence package (important for KB curation)

• A dedicated MONDO/MeSH/ICD identifier for “FGFR‑altered UC” was not established in the retrieved evidence; the subtype is best represented as urothelial carcinoma with a biomarker attribute.
• Several guideline-level resources (e.g., NCCN/EAU) and FDA label documents were not directly retrieved here; companion diagnostic claims are therefore cited from peer‑reviewed sources that mention therascreen as the companion diagnostic (bannier2024aiallowsprescreening pages 2-3, jain2024acomprehensiveoverview pages 8-10).
• Symptom frequencies specifically in FGFR‑altered vs FGFR‑wildtype UC were not available in extracted evidence; phenotypes are described at the UC level.

References

1. (guercio2023clinicalandgenomic pages 2-4): Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A. Funt, Chung-Han Lee, David H. Aggen, Ashley M. Regazzi, Ziyu Chen, Michael Lattanzi, Hikmat A. Al-Ahmadie, A. Rose Brannon, Ronak Shah, Carissa Chu, Andrew T. Lenis, Eugene Pietzak, Bernard H. Bochner, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin, and Gopa Iyer. Clinical and genomic landscape of fgfr3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research, 29:4586-4595, Sep 2023. URL: https://doi.org/10.1158/1078-0432.ccr-23-1283, doi:10.1158/1078-0432.ccr-23-1283. This article has 62 citations.

2. (testi2024targetedtherapiesand pages 11-13): Irene Testi, Giulia Claire Giudice, Giuseppe Salfi, Martino Pedrani, Sara Merler, Fabio Turco, Luigi Tortola, and Ursula Vogl. Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives. Exploration of Targeted Anti-tumor Therapy, 5:1326-1364, Nov 2024. URL: https://doi.org/10.37349/etat.2024.00279, doi:10.37349/etat.2024.00279. This article has 3 citations.

3. (benjamin2023treatmentapproachesfor pages 3-4): David J. Benjamin and Robert Hsu. Treatment approaches for fgfr-altered urothelial carcinoma: targeted therapies and immunotherapy. Frontiers in Immunology, Aug 2023. URL: https://doi.org/10.3389/fimmu.2023.1258388, doi:10.3389/fimmu.2023.1258388. This article has 18 citations and is from a peer-reviewed journal.

4. (guercio2023clinicalandgenomic pages 6-7): Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A. Funt, Chung-Han Lee, David H. Aggen, Ashley M. Regazzi, Ziyu Chen, Michael Lattanzi, Hikmat A. Al-Ahmadie, A. Rose Brannon, Ronak Shah, Carissa Chu, Andrew T. Lenis, Eugene Pietzak, Bernard H. Bochner, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin, and Gopa Iyer. Clinical and genomic landscape of fgfr3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research, 29:4586-4595, Sep 2023. URL: https://doi.org/10.1158/1078-0432.ccr-23-1283, doi:10.1158/1078-0432.ccr-23-1283. This article has 62 citations.

5. (bannier2024aiallowsprescreening pages 1-2): Pierre-Antoine Bannier, Charlie Saillard, Philipp Mann, Maxime Touzot, Charles Maussion, Christian Matek, Niklas Klümper, Johannes Breyer, Ralph Wirtz, Danijel Sikic, Bernd Schmitz-Dräger, Bernd Wullich, Arndt Hartmann, Sebastian Försch, and Markus Eckstein. Ai allows pre-screening of fgfr3 mutational status using routine histology slides of muscle-invasive bladder cancer. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-55331-6, doi:10.1038/s41467-024-55331-6. This article has 20 citations and is from a highest quality peer-reviewed journal.

6. (antar2024theevolvingmolecular pages 3-5): Ryan Michael Antar, Christopher Fawaz, Diego Gonzalez, Vincent Eric Xu, Arthur Pierre Drouaud, Jason Krastein, Faozia Pio, Andeulazia Murdock, Kirolos Youssef, Stanislav Sobol, and Michael J. Whalen. The evolving molecular landscape and actionable alterations in urologic cancers. Current Oncology, 31:6909-6937, Nov 2024. URL: https://doi.org/10.3390/curroncol31110511, doi:10.3390/curroncol31110511. This article has 5 citations.

7. (shang2024landscapeoftargeted pages 3-5): Shihao Shang, Lei Zhang, Kepu Liu, Maoxin Lv, Jie Zhang, Dongen Ju, Di Wei, Zelong Sun, Pinxiao Wang, Jianlin Yuan, and Zheng Zhu. Landscape of targeted therapies for advanced urothelial carcinoma. Exploration of Targeted Anti-tumor Therapy, 5:641-677, Jun 2024. URL: https://doi.org/10.37349/etat.2024.00240, doi:10.37349/etat.2024.00240. This article has 5 citations.

8. (guercio2023clinicalandgenomic pages 1-2): Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A. Funt, Chung-Han Lee, David H. Aggen, Ashley M. Regazzi, Ziyu Chen, Michael Lattanzi, Hikmat A. Al-Ahmadie, A. Rose Brannon, Ronak Shah, Carissa Chu, Andrew T. Lenis, Eugene Pietzak, Bernard H. Bochner, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin, and Gopa Iyer. Clinical and genomic landscape of fgfr3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research, 29:4586-4595, Sep 2023. URL: https://doi.org/10.1158/1078-0432.ccr-23-1283, doi:10.1158/1078-0432.ccr-23-1283. This article has 62 citations.

9. (shan2024moleculartargetingof pages 4-5): Khine S. Shan, Shivani Dalal, Nyein Nyein Thaw Dar, Omani McLish, Matthew Salzberg, and Brian A. Pico. Molecular targeting of the fibroblast growth factor receptor pathway across various cancers. International Journal of Molecular Sciences, 25:849, Jan 2024. URL: https://doi.org/10.3390/ijms25020849, doi:10.3390/ijms25020849. This article has 24 citations.

10. (mitiushkina2024useof3′ pages 1-2): Natalia V. Mitiushkina, Vladislav I. Tiurin, Aleksandra A. Anuskina, Natalia A. Bordovskaya, Ekaterina A. Nalivalkina, Darya M. Terina, Mariya V. Berkut, Anna D. Shestakova, Maria V. Syomina, Ekaterina Sh. Kuligina, Alexandr V. Togo, and Evgeny N. Imyanitov. Use of 3′ rapid amplification of cdna ends (3′ race)-based targeted rna sequencing for profiling of druggable genetic alterations in urothelial carcinomas. International Journal of Molecular Sciences, 25:12126, Nov 2024. URL: https://doi.org/10.3390/ijms252212126, doi:10.3390/ijms252212126. This article has 1 citations.

11. (ferreira2023epimarkersforbladder pages 19-26): MFS Ferreira. Epimarkers for bladder cancer diagnosis and monitoring (epiblac). Unknown journal, 2023.

12. (ferreira2023epimarkersforbladder pages 26-29): MFS Ferreira. Epimarkers for bladder cancer diagnosis and monitoring (epiblac). Unknown journal, 2023.

13. (komura2023theimpactof pages 1-2): Kazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, Takuya Tsujino, Kazuki Nishimura, Mitsuaki Ishida, Takuo Hayashi, Ayako Ura, Takaya Ohno, Shogo Yamazaki, Keita Nakamori, Shoko Kinoshita, Ryoichi Maenosono, Masahiko Ajiro, Yuki Yoshikawa, Tomoaki Takai, Takeshi Tsutsumi, Kohei Taniguchi, Tomohito Tanaka, Kiyoshi Takahara, Tsuyoshi Konuma, Teruo Inamoto, Yoshinobu Hirose, Fumihito Ono, Yuichi Shiraishi, Akihide Yoshimi, and Haruhito Azuma. The impact of fgfr3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer. Molecular Cancer, Nov 2023. URL: https://doi.org/10.1186/s12943-023-01897-6, doi:10.1186/s12943-023-01897-6. This article has 50 citations and is from a highest quality peer-reviewed journal.

14. (mitiushkina2024useof3′ pages 2-3): Natalia V. Mitiushkina, Vladislav I. Tiurin, Aleksandra A. Anuskina, Natalia A. Bordovskaya, Ekaterina A. Nalivalkina, Darya M. Terina, Mariya V. Berkut, Anna D. Shestakova, Maria V. Syomina, Ekaterina Sh. Kuligina, Alexandr V. Togo, and Evgeny N. Imyanitov. Use of 3′ rapid amplification of cdna ends (3′ race)-based targeted rna sequencing for profiling of druggable genetic alterations in urothelial carcinomas. International Journal of Molecular Sciences, 25:12126, Nov 2024. URL: https://doi.org/10.3390/ijms252212126, doi:10.3390/ijms252212126. This article has 1 citations.

15. (okato2024fgfrinhibitionaugments pages 1-2): Atsushi Okato, Takanobu Utsumi, Michela Ranieri, Xingnan Zheng, Mi Zhou, Luiza D. Pereira, Ting Chen, Yuki Kita, Di Wu, Hyesun Hyun, Hyojin Lee, Andrew S. Gdowski, John D. Raupp, Sean Clark-Garvey, Ujjawal Manocha, Alison Chafitz, Fiona Sherman, Janaye Stephens, Tracy L. Rose, Matthew I. Milowsky, Sara E. Wobker, Jonathan S. Serody, Jeffrey S. Damrauer, Kwok-Kin Wong, and William Y. Kim. Fgfr inhibition augments anti–pd-1 efficacy in murine fgfr3-mutant bladder cancer by abrogating immunosuppression. The Journal of Clinical Investigation, Jan 2024. URL: https://doi.org/10.1172/jci169241, doi:10.1172/jci169241. This article has 32 citations.

16. (bannier2024aiallowsprescreening pages 2-3): Pierre-Antoine Bannier, Charlie Saillard, Philipp Mann, Maxime Touzot, Charles Maussion, Christian Matek, Niklas Klümper, Johannes Breyer, Ralph Wirtz, Danijel Sikic, Bernd Schmitz-Dräger, Bernd Wullich, Arndt Hartmann, Sebastian Försch, and Markus Eckstein. Ai allows pre-screening of fgfr3 mutational status using routine histology slides of muscle-invasive bladder cancer. Nature Communications, Dec 2024. URL: https://doi.org/10.1038/s41467-024-55331-6, doi:10.1038/s41467-024-55331-6. This article has 20 citations and is from a highest quality peer-reviewed journal.

17. (jain2024acomprehensiveoverview pages 8-10): Nem Kumar Jain, Mukul Tailang, Neelaveni Thangavel, Hafiz A. Makeen, Mohammed Albratty, Asim Najmi, Hassan Ahmad Alhazmi, Khalid Zoghebi, Muthumanickam Alagusundaram, Hemant Kumar Jain, and Balakumar Chandrasekaran. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality. Acta Pharmaceutica, 74:1-36, Mar 2024. URL: https://doi.org/10.2478/acph-2024-0005, doi:10.2478/acph-2024-0005. This article has 7 citations and is from a peer-reviewed journal.

18. (guercio2023clinicalandgenomic media 250123eb): Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A. Funt, Chung-Han Lee, David H. Aggen, Ashley M. Regazzi, Ziyu Chen, Michael Lattanzi, Hikmat A. Al-Ahmadie, A. Rose Brannon, Ronak Shah, Carissa Chu, Andrew T. Lenis, Eugene Pietzak, Bernard H. Bochner, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin, and Gopa Iyer. Clinical and genomic landscape of fgfr3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research, 29:4586-4595, Sep 2023. URL: https://doi.org/10.1158/1078-0432.ccr-23-1283, doi:10.1158/1078-0432.ccr-23-1283. This article has 62 citations.

19. (NCT06995677 chunk 1): Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer. Tyra Biosciences, Inc. 2025. ClinicalTrials.gov Identifier: NCT06995677

20. (testi2024targetedtherapiesand pages 4-6): Irene Testi, Giulia Claire Giudice, Giuseppe Salfi, Martino Pedrani, Sara Merler, Fabio Turco, Luigi Tortola, and Ursula Vogl. Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives. Exploration of Targeted Anti-tumor Therapy, 5:1326-1364, Nov 2024. URL: https://doi.org/10.37349/etat.2024.00279, doi:10.37349/etat.2024.00279. This article has 3 citations.

21. (NCT04917809 chunk 2): A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer. Memorial Sloan Kettering Cancer Center. 2022. ClinicalTrials.gov Identifier: NCT04917809

22. (noeraparast2024fgfr3alterationsin pages 1-2): Maxim Noeraparast, Katarina Krajina, Renate Pichler, Dora Niedersüß‐Beke, Shahrokh F Shariat, Viktor Grünwald, Sascha Ahyai, and Martin Pichler. Fgfr3 alterations in bladder cancer: sensitivity and resistance to targeted therapies. Cancer Communications, 44:1189-1208, Aug 2024. URL: https://doi.org/10.1002/cac2.12602, doi:10.1002/cac2.12602. This article has 26 citations.

23. (guercio2023clinicalandgenomic pages 13-14): Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, Neha Ratna, Cihan Duzgol, Samuel A. Funt, Chung-Han Lee, David H. Aggen, Ashley M. Regazzi, Ziyu Chen, Michael Lattanzi, Hikmat A. Al-Ahmadie, A. Rose Brannon, Ronak Shah, Carissa Chu, Andrew T. Lenis, Eugene Pietzak, Bernard H. Bochner, Michael F. Berger, David B. Solit, Jonathan E. Rosenberg, Dean F. Bajorin, and Gopa Iyer. Clinical and genomic landscape of fgfr3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clinical cancer research : an official journal of the American Association for Cancer Research, 29:4586-4595, Sep 2023. URL: https://doi.org/10.1158/1078-0432.ccr-23-1283, doi:10.1158/1078-0432.ccr-23-1283. This article has 62 citations.